GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » Cyclically Adjusted PS Ratio

Trinity Biotech (Trinity Biotech) Cyclically Adjusted PS Ratio : 0.08 (As of May. 17, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Trinity Biotech Cyclically Adjusted PS Ratio?

As of today (2024-05-17), Trinity Biotech's current share price is $1.58. Trinity Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $19.86. Trinity Biotech's Cyclically Adjusted PS Ratio for today is 0.08.

The historical rank and industry rank for Trinity Biotech's Cyclically Adjusted PS Ratio or its related term are showing as below:

TRIB' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.08   Med: 1.05   Max: 3.44
Current: 0.08

During the past years, Trinity Biotech's highest Cyclically Adjusted PS Ratio was 3.44. The lowest was 0.08. And the median was 1.05.

TRIB's Cyclically Adjusted PS Ratio is ranked better than
96.99% of 133 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.4 vs TRIB: 0.08

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Trinity Biotech's adjusted revenue per share data for the three months ended in Dec. 2023 was $1.062. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $19.86 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Trinity Biotech Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Trinity Biotech's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech Cyclically Adjusted PS Ratio Chart

Trinity Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 1.00 0.36 0.24 0.11

Trinity Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.23 0.23 0.18 0.11

Competitive Comparison of Trinity Biotech's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, Trinity Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trinity Biotech's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Trinity Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's Cyclically Adjusted PS Ratio falls into.



Trinity Biotech Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Trinity Biotech's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.58/19.86
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Trinity Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Trinity Biotech's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.062/120.7486*120.7486
=1.062

Current CPI (Dec. 2023) = 120.7486.

Trinity Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 5.168 100.573 6.205
201406 5.490 100.773 6.578
201409 5.736 100.474 6.893
201412 5.627 99.576 6.823
201503 5.346 99.975 6.457
201506 4.210 100.573 5.055
201509 4.478 100.274 5.392
201512 4.346 99.676 5.265
201603 4.103 99.676 4.970
201606 4.627 101.072 5.528
201609 4.603 100.274 5.543
201612 4.224 99.676 5.117
201703 4.301 100.374 5.174
201706 4.694 100.673 5.630
201709 4.806 100.474 5.776
201712 4.647 100.075 5.607
201803 4.548 100.573 5.460
201806 4.779 101.072 5.709
201809 4.532 101.371 5.398
201812 4.898 100.773 5.869
201903 4.324 101.670 5.135
201906 4.416 102.168 5.219
201909 4.828 102.268 5.700
201912 4.185 102.068 4.951
202003 4.157 102.367 4.903
202006 3.090 101.769 3.666
202009 6.082 101.072 7.266
202012 7.839 101.072 9.365
202103 5.649 102.367 6.663
202106 6.183 103.364 7.223
202109 5.040 104.859 5.804
202112 0.970 106.653 1.098
202203 3.189 109.245 3.525
202206 2.270 112.779 2.430
202209 2.060 113.504 2.191
202212 2.061 115.436 2.156
202303 1.943 117.609 1.995
202306 1.815 119.662 1.831
202309 1.915 120.749 1.915
202312 1.062 120.749 1.062

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Trinity Biotech  (NAS:TRIB) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Trinity Biotech Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Trinity Biotech (Trinity Biotech) Business Description

Traded in Other Exchanges
Address
IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.